15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for LTRN yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $2.89 current
Highest Target—
Average Target—
Lowest Target—
LTRN analyst recommendation trends
86420
Jul
Aug
Sep
Oct
Nov
Dec
Jan
Feb
Mar
Strong BuyBuyHoldSellStrong Sell
RATING
OCT
NOV
DEC
JAN
FEB
MAR
Strong Buy
0
0
0
0
0
0
Buy
1
1
1
1
1
1
Hold
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of Mar, 1 of 1 firms rate LTRN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LTRN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.38 – $-0.38 · 1 analysts · -3% YoY
Next period, 1 analysts expect Lantern Pharma Inc to earn $-0.38 a share (range $-0.38 – $-0.38), versus $-0.39 a year earlier. Full-year consensus is $-1.51, growing to $-2.02 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Lantern Pharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LTRN.
#1
CM
Chad Messer
Lake Street
Buy
$25.00+765.1% to target
Coverage
—
+ Follow
LTRN stock forecast FAQ
Who is the most accurate analyst covering LTRN?+
Among analysts who currently cover LTRN, Chad Messer of Lake Street has the strongest overall Quantellect track record. Their current call is Buy with a $25.00 target.
What is Lantern Pharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.38 – $-0.38) across 1 analysts. Full-year EPS is projected at $-1.51, rising to $-2.02 the following year.
How much revenue is Lantern Pharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading LTRN lately?+
As of Mar, 1 of 1 firms rate LTRN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LTRN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
